Prelude Therapeutics Incorporated announced a multi-year, multi-program partnership with Canada-based ABCellra to discover, develop, and commercialize potentially treatments for patients with cancer.
“By leveraging our combined capabilities and expertise in rapidly discovering and advancing novel candidates into the clinic, this collaboration provides an opportunity to build a pipeline of first-in-class ADCs targeting clinically validated pathways in oncology,” said Kris Vaddi, CEO of Prelude.
Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration. AbCellera will lead manufacturing activities and Prelude will lead clinical development and global commercialization, subject to AbCellera’s option to co-promote any resulting commercial products in the United States. Prelude Therapeutics, based near Wilmington, is a clinical-stage precision oncology company developing drug candidates targeting critical cancer cell pathways. The company is publicly traded and has a stock value of $1.6 billion.